AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

In the 445-person TRIUMPH-4 trial, weekly retatrutide was associated with larger reductions in knee osteoarthritis pain and disability than placebo over 68 weeks. Participants taking retatrutide also lost more than one-quarter of their body weight, while withdrawals due to adverse events were more common; the drug remains investigational.

Retatrutide reduced knee pain and disability more than placebo over 68 weeks in adults with obesity and knee osteoarthritis, according to results from the 445-participant TRIUMPH-4 trial presented at the American College of Rheumatology annual meeting and published in the New England Journal of Medicine. Participants assigned the investigational weekly injection also lost more than one-quarter of their body weight, but adverse-event withdrawals were higher than in the placebo group.

Gift ideaOffer from Amazon

Give the gift of listening to someone you love

  • Choose a 1-, 3-, 6- or 12-month membership
  • They pick the audiobooks they love
  • Easy to send by email
Give Audible Delivered by email · No shipping needed
As an affiliate, we earn on qualifying purchases.

Researchers randomized 445 adults with obesity and knee osteoarthritis to weekly injections of placebo, 9 milligrams of retatrutide or 12 milligrams. The trial ran for 68 weeks. Participants had a mean baseline body mass index of 40.4 and an average body weight of 113 kilograms, or about 249 pounds. The study included participants from the United States, Canada, Mexico, Australia and Spain.

The primary pain measure was the WOMAC pain score, which assesses symptoms reported by people with osteoarthritis. Scores fell by an average of 4.48 points with the 9-mg dose and 4.41 points with the 12-mg dose, compared with a 2.43-point decline with placebo. WOMAC physical-function scores also improved more in the retatrutide groups: by 4.14 and 4.20 points, respectively, compared with 2.06 points with placebo. Higher scores indicate worse disability.

Participants in both retatrutide groups lost more than one-quarter of their body weight by week 68, the report said. Weight loss and pain relief also occurred in the placebo group, whose participants received individualized dietary counseling and were encouraged to do at least 150 minutes of physical activity per week. The article reported that some participants receiving retatrutide left the trial because they considered their weight loss excessive.

Adverse effects led 13% of participants in the 9-mg group and 18% in the 12-mg group to withdraw, compared with 4% of those assigned placebo. Serious adverse events were reported in about 10% of participants in each retatrutide group and 2% in the placebo group. Gastrointestinal effects were the most common adverse events described in the report.

At a glance
reportWhen: Reported November 8, 2026; 68-week tria…
The developmentResults from the TRIUMPH-4 trial of investigational retatrutide for people with obesity and knee osteoarthritis were presented at the American College of Rheumatology meeting and published in the New England Journal of Medicine.

Pain Relief Alongside Major Weight Loss

The results matter because knee osteoarthritis can limit mobility, and excess body weight can contribute to the load on the knee. A treatment that produces substantial weight loss while improving pain and function could address two problems at once for people who have both obesity and osteoarthritis. The trial’s results add evidence to growing interest in weight-loss medicines as a possible part of osteoarthritis care.

But the findings do not establish that retatrutide directly treats joint disease or slows joint damage. Pain improvement could be related to lower mechanical loading after weight loss, changes in inflammation, or other factors. The trial also compared the drug with placebo on top of diet and activity support, so the results reflect the full study setting rather than medication in isolation. Higher adverse-event withdrawal rates are also relevant when weighing the size of the reported benefits.

Products Worth Considering

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG

As an affiliate, we earn on qualifying purchases.

How Retatrutide Differs From Other Drugs

Retatrutide is an investigational triple-receptor drug that acts on receptors for GLP-1, GIP and glucagon. It is not the same as established single-target GLP-1 medicines, and the source report describes prior trials as showing greater weight loss than is typically seen with some existing drugs. Those comparisons do not establish how the medicines would perform against one another in this osteoarthritis trial.

TRIUMPH-4 followed the TRIUMPH-1 study, which had been reported earlier in 2026. The study report appeared alongside a recap of TRIUMPH-1 in the New England Journal of Medicine. Researchers encouraged all TRIUMPH-4 participants to pursue dietary changes and physical activity, a design detail that may help explain the improvement among placebo recipients as well as the drug groups.

Lead investigator Thomas Conaghan of the University of Leeds said that 64% of participants had Kellgren-Lawrence grade 3 osteoarthritis, indicating substantial joint damage. The reported pain changes therefore came from a group that included many people with notable structural disease, though the trial results do not show that the joint damage itself was reversed.

Mechanism and Joint Effects Still Unknown

The trial results do not show why pain improved or whether retatrutide changes the underlying osteoarthritis. Reduced body weight may ease knee loading; the authors also raised the possibility that changes in adipose tissue and inflammatory signals could contribute. The report says the precise mechanism was not discussed by Conaghan, and the authors called for further research.

It is also unclear from the report whether the findings would apply to people with osteoarthritis who do not have obesity, or whether the degree of weight loss would be appropriate for every patient. The study enrolled people with obesity, had a mean baseline BMI of 40.4, and included lifestyle support. Longer-term outcomes, including whether pain relief lasts and whether joint damage progresses differently, are not established by the reported results. Retatrutide remains investigational, and the supplied report does not give a regulatory decision or a complete breakdown of all adverse events.

Further Trials Must Test Durability

The next research questions include whether retatrutide’s pain and function benefits persist beyond the 68-week trial, how its benefits compare with its adverse effects in broader patient groups, and whether it can alter osteoarthritis progression rather than only symptoms. Further studies could also examine the role of weight loss, knee loading and inflammation in the observed changes.

For now, the reported findings are evidence from a clinical trial, not confirmation that retatrutide is an approved osteoarthritis treatment. The source material does not specify a regulatory timeline or the next planned trial milestone. Any future conclusions about use would depend on additional evidence and decisions by regulators.

Key Questions

What did the TRIUMPH-4 trial find?

Over 68 weeks, average WOMAC pain scores fell by 4.48 points with 9-mg retatrutide and 4.41 points with 12-mg retatrutide, compared with a 2.43-point decrease with placebo. Physical-function scores also improved more in the retatrutide groups.

How much weight did participants lose?

The report says participants assigned retatrutide lost more than one-quarter of their body weight by week 68. Participants in all groups received dietary counseling and activity guidance, and some people taking retatrutide withdrew because they considered their weight loss excessive.

Did retatrutide reverse knee osteoarthritis?

The reported results show improvements in pain and physical function, but they do not show that retatrutide reversed joint damage or slowed osteoarthritis progression. The study authors called for further research into whether it could act as a disease-modifying treatment.

What adverse events were reported?

Adverse events led to withdrawals in 13% of participants taking 9 mg and 18% taking 12 mg, compared with 4% on placebo. Serious adverse events were reported in about 10% of both retatrutide groups and 2% of the placebo group; gastrointestinal effects were the most common described.

Is retatrutide available as an osteoarthritis treatment?

Retatrutide is described in the report as investigational. The supplied material does not report a regulatory approval for osteoarthritis or a timeline for one.

Source: medpagetoday.com

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

How Intimacy And Sexuality Can Support Healthy Aging After 60

A Sixty and Me report explains how intimacy can fit into healthy aging after 60, while noting the limits of evidence linking sex and well-being.

Factors That Speed Up Aging

A study of 726 midlife women links aging anxiety to faster epigenetic aging. Harvard geneticist David Sinclair outlines what speeds up and slows biological age.

Testosterone For Menopause May Carry Heart Risks

A retrospective study found higher cardiovascular event rates among postmenopausal testosterone users, but researchers say it cannot establish cause and effect.

When You Can’t Get Everything Right At Once

In a Tiny Buddha essay, psychotherapist Steve Hauptman reflects on control, competing priorities and accepting that choices come with trade-offs.